"Studies in the rat following oral administration at dosage levels up to 50 mcg/kg per day revealed that the females exhibited an increase in the number of resorbed embryos and a decrease in the number of living fetuses at the highest dose. Pregnancy: Teratogenic Effects (., possibility of causing abnormalities in fetuses): Pregnancy Category C: Clobetasol propionate has not been tested for teratogenicity when applied topically; however, it is absorbed percutaneously, and when administered subcutaneously it was a significant teratogen in both the rabbit and mouse. Clobetasol propionate has greater teratogenic potential than steroids that are less are no adequate and well-controlled studies of the teratogenic effects of clobetasol propionate in pregnant women. Temovate Cream and Ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."
Danazol is metabolized in the liver by enzymes such as CYP3A4 .   Its elimination half-life has varied across studies, but has been found to be 3 to 10 hours after a single dose and 24 to 26 hours with repeated administration.   The major metabolites of danazol are 2-hydroxymethylethisterone (also known as 2-hydroxymethyldanazol; formed by CYP3A4 and described as inactive) and ethisterone (a progestogen and androgen),     and other, minor metabolites include δ 2 -hydroxymethylethisterone, 6β-hydroxy-2-hydroxymethylethisterone, and δ 1 -6β-hydroxy-2-hydroxymethylethisterone.  At least 10 different metabolites have been identified.  Danazol is eliminated in urine and feces , with the two primary metabolites in urine being 2-hydroxymethylethisterone and ethisterone. 
In moderate to severe plaque-type psoriasis, Clobetasol Propionate Cream (Emollient) applied to 5 - 10% of body surface area can be used for up to 4 weeks. The total dose should not exceed 50 g per week. When dosing for more than 2 weeks, any additional benefits of extending treatment should be weighed against the risk of HPA suppression. Therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Treatment beyond 4 consecutive weeks is not recommended. Use in pediatric patients under 16 years of age has not been studied.